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Introduction
From the end of 2019 until present and
into the foreseeable future, SARS-CoV-2,
or Coronavirus disease 2019 (COVID19), has been in the forefront of our
concerns. Having a novel virus at the
root of a pandemic, limited information
is available, especially initially, on the
scope of the signs and symptoms,
effective treatment, and the extent of the
lasting effects, as well as the many other
aspects involved with this illness. As
time has passed, it has been realized that
the virus leaves many in a
hypercoagulable state (Abou-Ismail et
al., 2020).
To effectively treat those afflicted with
this specific symptom of COVID-19, an
understanding of the pathophysiology of
the virus must be established to
effectively treat and potentially prevent
coagulopathy and the thrombotic events
that can ensue. Gaining more insight into
this will allow for standardized plan of
care that includes appropriate
predicative labs and effective
prophylactic medications to be utilized
in outpatient or inpatient settings to
prevent a hypercoagulable state from
occurring or minimize the medical
effects of a thrombotic event.

Pathophysiological Processes
Underlying
Pathophysiology
There are a several coagulation
abnormalities that have been revealed in
individuals diagnosed with COVID-19.
As with many infections or
inflammatory responses, a
hypercoagulable state can emerge.
These are familiarly classified under
Virchow’s Triad:
1.

Injury to vessel endothelium –
research shows that the virus
directly attacks endothelial cells.
Endothelialitis is a significant
contributor to thrombosis
formation.

2.

Abnormalities of Blood Flow, or
Stasis – for most patients with
COVID-19, this is in direct
response to decreased mobility
in light of the extenuating
symptoms of the virus, especially
with hospitalized individuals.

3.

Hypercoagulability of the Blood –
this is caused by the
inflammatory state of the virus or
infection.

Significance of
Pathophysiology

Venous Thromnoembolism Pulmonary embolism (PE) is the most
common expression. Post-mortem
examinations have consistently
revealed PE’s and microthrombi in
alveolar capillaries. . (Abou-Ismail et
al., 2020) Deep Vein Thrombosis
(DVT) are commonly seen as well
and have been found to impact the
bilateral lower extremities.

•

Stroke – Ischemic strokes have been
seen as the typical manifestation,
along with limb ischemia, both of
which are more noted in large
vessels.

•

The spike protein found on SARSCoV-2 has been linked to activating a
dysregulated alternative complement
pathway, causing a cytokine storm.

•

Figure A. (Sars-cov-2 (2019-ncov) proteins 2020)

Monitoring cogualation abnormalities
via serum laboratory testing has been a
key indicator in determining
hypercoagulable diagnoses. The
standard set of test to offer the most
insight are:

“The novel SARS-CoV-2 appears to
generate a profoundly prothrombotic
milieu as evidenced by a surge in global
reports of arterial, venous and catheterrelated thrombosis (Abou-Ismail et al.,
2020). While there are similarities shared
with other viruses and responses, there
are several points of distinction with the
hypercoagulable state seen with COVID19.:
•

The spike protein found on SARSCoV-2 has been linked to a
derangement in the ReninAngiotensin-Aldosterone pathway,
which contributes to the
hypercogulable state.

Implications for Nursing Care
Once a confirmation of a thrombotic
event has been made, there are several
courses of treatment that can be
administered to effectively mitigate the
situation. The most common and most
effective are:

•

Abnormal or slightly prolonged
Prothrombin Time AND aPTT

•

Low-Molecular Weight Heparin at a
moderate to full-dose

•

Platelet counts normal or slightly
increased.

•

•

Fibrinogen increased

Tissue Plasminogen Activator in
cases of a massive and/or
obstructive PE, Central-line
associated thrombosis, limbthreatening DVT or acute stroke.

•

D-Dimer increased.

Along with any of these abnormalities, in
order to definitely detect and diagnoses a
hypercoagulable manifestation,
ultrasound imaging has been found to
offer the most insight in locating the
impacted area of a DVT, while a CT is
used to confirm a PE.

Figure B. Pathophysiology of the Hypercoagulable State in COVID-19. The current
understanding of the pathophysiology of COVID-19 induced coagulopathy centers
around the bidirectional cross-talk between inflammation (yellow arrows) and
thrombosis (black arrows). COVID-19 leads to a severe inflammatory response
that originates in the alveoli. Release of inflammatory cytokines leads to
activation of epithelial cells, monocytes and macrophages. Direct infection of the
endothelial cells through the ACE2 receptor also leads to endothelial activation
and dysfunction,, all of which contribute to thrombin generation and fibrin clot
formation. Thrombin, in turn, causes inflammation through its effect on platelets
which promote NET formation in neutrophils. It also activates endothelium
through the PAR receptor, which leads to release of C5A that further activates
monocytes. These mechanisms are currently hypothetical based on existing
findings in COVID-19 and previous understanding of the cross-talk between
inflammation and thrombosis. ACE2: Angiotensin-converting enzyme 2. FVIII:
Factor VIII. IL: Interleukin. NET: Neutrophil extracellular trap. TF: Tissue factor.
TNF: Tumor necrosis factor. VWF: von Willebrand factor. (Abou-Ismail et al.,
2020)

Conclusions
Though the research is technically incomplete at this time due to the novelty of the
virus, there is reliable and valuable information available to be extracted, applied and
utilized in the clinical setting to mitigate the mortality risk of patients diagnosed with
COVID-19.
Understanding the causative factors in the pathophysiological process of the
hypercoagulable state allows for more strategic management of patients’ conditions.
Insight is given into serum laboratory tests to monitor, imaging to perform and
therapeutic medicinal management to implement. These interventional strategies
allow clinicians an opportunity to prevent further complications of the virus for their
patients.
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